Intensive outpatient adjuvant therapy for breast cancer

Results of dose escalation and quality of life

S. M. Swain, J. Rowland, K. Weinfurt, C. Berg, Marc E Lippman, L. Walton, E. Egan, D. King, I. Spertus, S. F. Honig

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Purpose: A dose-escalation study was conducted to determine the maximum- tolerated dose (MTD) and dose-limiting toxicities (DLTs) of cyclophosphamide (CY) in combination with granulocyte colony-stimulating factor (G-CSF) and doxorubicin (DOX) given every 2 weeks for eight cycles as outpatient adjuvant therapy for node-positive breast cancer. A pilot study to assess quality of life (QOL) was performed. Patients and Methods: From March 1991 to April 1993, 19 patients were entered. Patients received escalating doses of CY intravenously (IV) {1,000 mg/m2, 1,500 mg/m2, 2,000 mg/m2, or 2,500 mg/m2) with DOX 40 mg/m2, G-CSF 10 μg/kg/d on days 2 to 12, and mesna, every 2 weeks for eight cycles. QOL was measured by the Profile of Mood States (POMS), the Psychosocial Adjustment to Illness Scale-Self Report (PAIS-SR), and a 27-item QOL scale. Results: The CY dose of 2,500 mg/m2 every 2 weeks elicited toxicities that required dose reductions secondary to a combination of thrombocytopenia, hematuria, and anemia that required transfusion. The dose of 2,000 mg/m2 resulted in an acceptable toxicity profile. Ninety-two percent of cycles at the 2,000-mg/m2 dose were delivered on schedule and 77% without hospitalization. QOL assessments indicated high levels of distress measured by POMS in 47%, poor overall quality of life in 40%, and significant problems with physical symptoms in less than 27% of all patients for any given cycle. Conclusion: A dose of CY at 2,000 mg/m2 can be administered every 2 weeks with DOX and G-CSF for eight cycles in the outpatient setting with manageable toxicity. The majority of women described levels of physical symptoms and emotional distress as tolerable during treatment.

Original languageEnglish
Pages (from-to)1565-1572
Number of pages8
JournalJournal of Clinical Oncology
Volume14
Issue number5
StatePublished - May 1 1996
Externally publishedYes

Fingerprint

Outpatients
Cyclophosphamide
Quality of Life
Breast Neoplasms
Granulocyte Colony-Stimulating Factor
Doxorubicin
Mesna
Therapeutics
Social Adjustment
Maximum Tolerated Dose
Hematuria
Thrombocytopenia
Self Report
Anemia
Appointments and Schedules
Hospitalization

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Swain, S. M., Rowland, J., Weinfurt, K., Berg, C., Lippman, M. E., Walton, L., ... Honig, S. F. (1996). Intensive outpatient adjuvant therapy for breast cancer: Results of dose escalation and quality of life. Journal of Clinical Oncology, 14(5), 1565-1572.

Intensive outpatient adjuvant therapy for breast cancer : Results of dose escalation and quality of life. / Swain, S. M.; Rowland, J.; Weinfurt, K.; Berg, C.; Lippman, Marc E; Walton, L.; Egan, E.; King, D.; Spertus, I.; Honig, S. F.

In: Journal of Clinical Oncology, Vol. 14, No. 5, 01.05.1996, p. 1565-1572.

Research output: Contribution to journalArticle

Swain, SM, Rowland, J, Weinfurt, K, Berg, C, Lippman, ME, Walton, L, Egan, E, King, D, Spertus, I & Honig, SF 1996, 'Intensive outpatient adjuvant therapy for breast cancer: Results of dose escalation and quality of life', Journal of Clinical Oncology, vol. 14, no. 5, pp. 1565-1572.
Swain SM, Rowland J, Weinfurt K, Berg C, Lippman ME, Walton L et al. Intensive outpatient adjuvant therapy for breast cancer: Results of dose escalation and quality of life. Journal of Clinical Oncology. 1996 May 1;14(5):1565-1572.
Swain, S. M. ; Rowland, J. ; Weinfurt, K. ; Berg, C. ; Lippman, Marc E ; Walton, L. ; Egan, E. ; King, D. ; Spertus, I. ; Honig, S. F. / Intensive outpatient adjuvant therapy for breast cancer : Results of dose escalation and quality of life. In: Journal of Clinical Oncology. 1996 ; Vol. 14, No. 5. pp. 1565-1572.
@article{d385980e952f47d9a5f49997438e8771,
title = "Intensive outpatient adjuvant therapy for breast cancer: Results of dose escalation and quality of life",
abstract = "Purpose: A dose-escalation study was conducted to determine the maximum- tolerated dose (MTD) and dose-limiting toxicities (DLTs) of cyclophosphamide (CY) in combination with granulocyte colony-stimulating factor (G-CSF) and doxorubicin (DOX) given every 2 weeks for eight cycles as outpatient adjuvant therapy for node-positive breast cancer. A pilot study to assess quality of life (QOL) was performed. Patients and Methods: From March 1991 to April 1993, 19 patients were entered. Patients received escalating doses of CY intravenously (IV) {1,000 mg/m2, 1,500 mg/m2, 2,000 mg/m2, or 2,500 mg/m2) with DOX 40 mg/m2, G-CSF 10 μg/kg/d on days 2 to 12, and mesna, every 2 weeks for eight cycles. QOL was measured by the Profile of Mood States (POMS), the Psychosocial Adjustment to Illness Scale-Self Report (PAIS-SR), and a 27-item QOL scale. Results: The CY dose of 2,500 mg/m2 every 2 weeks elicited toxicities that required dose reductions secondary to a combination of thrombocytopenia, hematuria, and anemia that required transfusion. The dose of 2,000 mg/m2 resulted in an acceptable toxicity profile. Ninety-two percent of cycles at the 2,000-mg/m2 dose were delivered on schedule and 77{\%} without hospitalization. QOL assessments indicated high levels of distress measured by POMS in 47{\%}, poor overall quality of life in 40{\%}, and significant problems with physical symptoms in less than 27{\%} of all patients for any given cycle. Conclusion: A dose of CY at 2,000 mg/m2 can be administered every 2 weeks with DOX and G-CSF for eight cycles in the outpatient setting with manageable toxicity. The majority of women described levels of physical symptoms and emotional distress as tolerable during treatment.",
author = "Swain, {S. M.} and J. Rowland and K. Weinfurt and C. Berg and Lippman, {Marc E} and L. Walton and E. Egan and D. King and I. Spertus and Honig, {S. F.}",
year = "1996",
month = "5",
day = "1",
language = "English",
volume = "14",
pages = "1565--1572",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "5",

}

TY - JOUR

T1 - Intensive outpatient adjuvant therapy for breast cancer

T2 - Results of dose escalation and quality of life

AU - Swain, S. M.

AU - Rowland, J.

AU - Weinfurt, K.

AU - Berg, C.

AU - Lippman, Marc E

AU - Walton, L.

AU - Egan, E.

AU - King, D.

AU - Spertus, I.

AU - Honig, S. F.

PY - 1996/5/1

Y1 - 1996/5/1

N2 - Purpose: A dose-escalation study was conducted to determine the maximum- tolerated dose (MTD) and dose-limiting toxicities (DLTs) of cyclophosphamide (CY) in combination with granulocyte colony-stimulating factor (G-CSF) and doxorubicin (DOX) given every 2 weeks for eight cycles as outpatient adjuvant therapy for node-positive breast cancer. A pilot study to assess quality of life (QOL) was performed. Patients and Methods: From March 1991 to April 1993, 19 patients were entered. Patients received escalating doses of CY intravenously (IV) {1,000 mg/m2, 1,500 mg/m2, 2,000 mg/m2, or 2,500 mg/m2) with DOX 40 mg/m2, G-CSF 10 μg/kg/d on days 2 to 12, and mesna, every 2 weeks for eight cycles. QOL was measured by the Profile of Mood States (POMS), the Psychosocial Adjustment to Illness Scale-Self Report (PAIS-SR), and a 27-item QOL scale. Results: The CY dose of 2,500 mg/m2 every 2 weeks elicited toxicities that required dose reductions secondary to a combination of thrombocytopenia, hematuria, and anemia that required transfusion. The dose of 2,000 mg/m2 resulted in an acceptable toxicity profile. Ninety-two percent of cycles at the 2,000-mg/m2 dose were delivered on schedule and 77% without hospitalization. QOL assessments indicated high levels of distress measured by POMS in 47%, poor overall quality of life in 40%, and significant problems with physical symptoms in less than 27% of all patients for any given cycle. Conclusion: A dose of CY at 2,000 mg/m2 can be administered every 2 weeks with DOX and G-CSF for eight cycles in the outpatient setting with manageable toxicity. The majority of women described levels of physical symptoms and emotional distress as tolerable during treatment.

AB - Purpose: A dose-escalation study was conducted to determine the maximum- tolerated dose (MTD) and dose-limiting toxicities (DLTs) of cyclophosphamide (CY) in combination with granulocyte colony-stimulating factor (G-CSF) and doxorubicin (DOX) given every 2 weeks for eight cycles as outpatient adjuvant therapy for node-positive breast cancer. A pilot study to assess quality of life (QOL) was performed. Patients and Methods: From March 1991 to April 1993, 19 patients were entered. Patients received escalating doses of CY intravenously (IV) {1,000 mg/m2, 1,500 mg/m2, 2,000 mg/m2, or 2,500 mg/m2) with DOX 40 mg/m2, G-CSF 10 μg/kg/d on days 2 to 12, and mesna, every 2 weeks for eight cycles. QOL was measured by the Profile of Mood States (POMS), the Psychosocial Adjustment to Illness Scale-Self Report (PAIS-SR), and a 27-item QOL scale. Results: The CY dose of 2,500 mg/m2 every 2 weeks elicited toxicities that required dose reductions secondary to a combination of thrombocytopenia, hematuria, and anemia that required transfusion. The dose of 2,000 mg/m2 resulted in an acceptable toxicity profile. Ninety-two percent of cycles at the 2,000-mg/m2 dose were delivered on schedule and 77% without hospitalization. QOL assessments indicated high levels of distress measured by POMS in 47%, poor overall quality of life in 40%, and significant problems with physical symptoms in less than 27% of all patients for any given cycle. Conclusion: A dose of CY at 2,000 mg/m2 can be administered every 2 weeks with DOX and G-CSF for eight cycles in the outpatient setting with manageable toxicity. The majority of women described levels of physical symptoms and emotional distress as tolerable during treatment.

UR - http://www.scopus.com/inward/record.url?scp=9244239744&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=9244239744&partnerID=8YFLogxK

M3 - Article

VL - 14

SP - 1565

EP - 1572

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 5

ER -